Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DengueTcP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Collaboration
Emergex Partners with DEKA for Assessment of Immunotherapeutic Candidates with Applicator
Details : The collaboration aims to assess the compatibility of Emergex’s immunotherapeutic candidates, including EMX-001 (dengueTcP) with the DEKA Intradermal Therapeutic Applicator.
Product Name : EMX-001
Product Type : Vaccine
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : DengueTcP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Emergex Vaccines Holding
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Zealand Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, DEKA and Zealand will develop a medical pump system that is suitable for use in combination with dasiglucagon. DEKA and its affiliates will be responsible for pump development and pump manufacturing activities.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Undisclosed
May 11, 2021
Lead Product(s) : Dasiglucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Zealand Pharma
Deal Size : Undisclosed
Deal Type : Collaboration